vs
BIOCRYST PHARMACEUTICALS INC（BCRX）与Ribbon Communications Inc.（RBBN）财务数据对比。点击上方公司名可切换其他公司
Ribbon Communications Inc.的季度营收约是BIOCRYST PHARMACEUTICALS INC的1.0倍（$162.6M vs $156.4M），BIOCRYST PHARMACEUTICALS INC同比增速更快（7.5% vs -10.3%），过去两年BIOCRYST PHARMACEUTICALS INC的营收复合增速更高（19.6% vs -8.1%）
BioCryst Pharmaceuticals是一家总部位于美国北卡罗来纳州达勒姆的制药企业，属于后期发展阶段的生物科技公司，聚焦于治疗罕见重症的口服药物研发。其研发的抗病毒药物帕拉米韦（商品名Rapivab）于2014年12月获得美国FDA批准，此后也陆续在日本、韩国与中国获批上市。
睿宾通信公司（Ribbon Communications Inc.）主要为电信运营商、企业及关键基础设施领域提供软件、IP与光网络解决方案。公司于2017年由Genband与Sonus Networks合并成立，总部位于美国得克萨斯州普莱诺，是一家上市科技企业。
BCRX vs RBBN — 直观对比
营收规模更大
RBBN
是对方的1.0倍
$156.4M
营收增速更快
BCRX
高出17.8%
-10.3%
两年增速更快
BCRX
近两年复合增速
-8.1%
损益表 — Q1 FY2026 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $156.4M | $162.6M |
| 净利润 | — | $89.1M |
| 毛利率 | — | 42.9% |
| 营业利润率 | 13.6% | 37.6% |
| 净利率 | — | 54.8% |
| 营收同比 | 7.5% | -10.3% |
| 净利润同比 | — | — |
| 每股收益（稀释后） | $0.00 | $0.50 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BCRXRBBN
| Q1 26 | $156.4M | $162.6M | ||
| Q4 25 | $406.6M | $227.3M | ||
| Q3 25 | $159.4M | $215.4M | ||
| Q2 25 | $163.4M | $220.6M | ||
| Q1 25 | $145.5M | $181.3M | ||
| Q4 24 | $131.5M | $251.4M | ||
| Q3 24 | $117.1M | $210.2M | ||
| Q2 24 | $109.3M | $192.6M |
净利润BCRXRBBN
| Q1 26 | — | $89.1M | ||
| Q4 25 | $245.8M | — | ||
| Q3 25 | $12.9M | $-12.1M | ||
| Q2 25 | $5.1M | $-11.1M | ||
| Q1 25 | $32.0K | $-26.2M | ||
| Q4 24 | $-26.8M | — | ||
| Q3 24 | $-14.0M | $-13.4M | ||
| Q2 24 | $-12.7M | $-16.8M |
毛利率BCRXRBBN
| Q1 26 | — | 42.9% | ||
| Q4 25 | 97.7% | 53.3% | ||
| Q3 25 | 98.6% | 50.1% | ||
| Q2 25 | 98.3% | 49.6% | ||
| Q1 25 | 96.9% | 45.4% | ||
| Q4 24 | 95.4% | 55.7% | ||
| Q3 24 | 97.3% | 52.1% | ||
| Q2 24 | 98.4% | 50.8% |
营业利润率BCRXRBBN
| Q1 26 | 13.6% | 37.6% | ||
| Q4 25 | 64.0% | 4.1% | ||
| Q3 25 | 18.6% | 1.3% | ||
| Q2 25 | 18.2% | 1.9% | ||
| Q1 25 | 14.6% | -10.8% | ||
| Q4 24 | -3.4% | 13.2% | ||
| Q3 24 | 6.6% | -0.4% | ||
| Q2 24 | 8.0% | -1.0% |
净利率BCRXRBBN
| Q1 26 | — | 54.8% | ||
| Q4 25 | 60.5% | — | ||
| Q3 25 | 8.1% | -5.6% | ||
| Q2 25 | 3.1% | -5.0% | ||
| Q1 25 | 0.0% | -14.5% | ||
| Q4 24 | -20.4% | — | ||
| Q3 24 | -12.0% | -6.4% | ||
| Q2 24 | -11.6% | -8.7% |
每股收益（稀释后）BCRXRBBN
| Q1 26 | $0.00 | $0.50 | ||
| Q4 25 | $1.13 | $0.50 | ||
| Q3 25 | $0.06 | $-0.07 | ||
| Q2 25 | $0.02 | $-0.06 | ||
| Q1 25 | $0.00 | $-0.15 | ||
| Q4 24 | $-0.13 | $0.05 | ||
| Q3 24 | $-0.07 | $-0.08 | ||
| Q2 24 | $-0.06 | $-0.10 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $259.0M | $67.6M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | — | $419.1M |
| 总资产 | $465.1M | — |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资BCRXRBBN
| Q1 26 | $259.0M | $67.6M | ||
| Q4 25 | $274.7M | $96.4M | ||
| Q3 25 | $212.9M | $74.8M | ||
| Q2 25 | $260.0M | $60.5M | ||
| Q1 25 | $295.1M | $71.2M | ||
| Q4 24 | $320.9M | $87.8M | ||
| Q3 24 | $96.8M | $37.2M | ||
| Q2 24 | $78.4M | $64.6M |
总债务BCRXRBBN
| Q1 26 | — | — | ||
| Q4 25 | — | $342.1M | ||
| Q3 25 | — | $344.3M | ||
| Q2 25 | — | $346.5M | ||
| Q1 25 | — | $347.4M | ||
| Q4 24 | — | $348.3M | ||
| Q3 24 | — | $349.1M | ||
| Q2 24 | — | $350.0M |
股东权益BCRXRBBN
| Q1 26 | — | $419.1M | ||
| Q4 25 | $-119.2M | $449.0M | ||
| Q3 25 | $-387.9M | $360.1M | ||
| Q2 25 | $-421.6M | $370.4M | ||
| Q1 25 | $-451.9M | $381.8M | ||
| Q4 24 | $-475.9M | $404.6M | ||
| Q3 24 | $-468.6M | $395.5M | ||
| Q2 24 | $-475.6M | $405.0M |
总资产BCRXRBBN
| Q1 26 | $465.1M | — | ||
| Q4 25 | $514.2M | $1.2B | ||
| Q3 25 | $446.4M | $1.1B | ||
| Q2 25 | $457.2M | $1.1B | ||
| Q1 25 | $480.0M | $1.1B | ||
| Q4 24 | $490.4M | $1.2B | ||
| Q3 24 | $491.3M | $1.1B | ||
| Q2 24 | $472.4M | $1.1B |
负债/权益比BCRXRBBN
| Q1 26 | — | — | ||
| Q4 25 | — | 0.76× | ||
| Q3 25 | — | 0.96× | ||
| Q2 25 | — | 0.94× | ||
| Q1 25 | — | 0.91× | ||
| Q4 24 | — | 0.86× | ||
| Q3 24 | — | 0.88× | ||
| Q2 24 | — | 0.86× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BCRX
| ORLADEYO | $148.3M | 95% |
| Other revenues | $5.0M | 3% |
| License revenue | $3.0M | 2% |
RBBN
| Service | $94.5M | 58% |
| Product | $68.1M | 42% |
